GlassScriptPhysician profile
Jagdeep Garewal
NPI 1427190487
$9,003.22
in general payments reported to CMS, 2019-2025
23 companies · $1,813 in 2025
The $1,813 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,806 · 2020: $326 · 2021: $890 · 2022: $929 · 2023: $1,933 · 2024: $1,307 · 2025: $1,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,889.83 |
| Education | $163.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,971.13 | 2019-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $1,680.71 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $765.84 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Lundbeck LLC | $698.29 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $683.51 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $518.10 | 2023-2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $457.63 | 2022-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $437.12 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $427.19 | 2019-2025 | Ingrezza |
| Abbvie INC. | $321.61 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $203.09 | 2021-2023 | Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $164.08 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $145.33 | 2025 | Fanapt |
| Allergan, INC. | $100.00 | 2019 | |
| Acadia Pharmaceuticals INC | $98.74 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $86.45 | 2021 | |
| Indivior INC. | $84.68 | 2019-2023 | Perseris |
| Bioxcel Therapeutics, INC. | $44.89 | 2023 | Igalmi |
| Sage Therapeutics, LLC | $35.24 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.26 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $25.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.33 | 2023 | Quviviq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagdeep Garewal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.